Reduced creatine kinase as a central and peripheral biomarker in Huntington's disease

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1802, Issue 7-8, 2010, Pages 673-681

  Kim, Jinho ^a,b   Amante, Daniel J ^a,b   Moody, Jennifer P ^a   Edgerly, Christina K ^a   Bordiuk, Olivia L ^a   Smith, Karen ^a,b   Matson, Samantha A ^a   Matson, Wayne R ^a   Scherzer, Clemens R ^c   Rosas, H Diana ^d   Hersch, Steven M ^d   Ferrante, Robert J ^a,b  

^a New England Veterans Administration VISN 1   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Biomarker; Blood buffy coat; Creatine kinase; Energetic defects; Huntington's disease

Indexed keywords

ALANINE; BIOLOGICAL MARKER; CREATINE KINASE BB; CYSTEINE; GLYCINE;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAG REPEAT; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DISEASE COURSE; DISEASE SEVERITY; HUMAN; HUMAN TISSUE; HUNTINGTON CHOREA; HYPOTHESIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

AGED; ANIMALS; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CENTRAL NERVOUS SYSTEM; CREATINE KINASE, BB FORM; DOWN-REGULATION; FEMALE; HUMANS; HUNTINGTON DISEASE; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED CBA; MICE, TRANSGENIC; MIDDLE AGED; POSTMORTEM CHANGES;

MUS;

EID: 77953806763     PISSN: 09254439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbadis.2010.05.001     Document Type: Article

References (52)

1. Stack E.C., Ferrante R.J. Huntington's disease: progress and potential in the field. Expert Opin Investig Drugs 2007, 16:1933-1953.
2. Brennan W.A., Bird E.D., Aprille J.R. Regional mitochondrial respiratory activity in Huntington's disease brain. J Neurochem 1985, 44:1948-1950.
3. Parker W.D., Boyson S.J., Luder A.S., Parks J.K. Evidence for a defect in NADH: ubiquinone oxidoreductase (complex I) in Huntington's disease. Neurology 1990, 40:1231-1234.
4. Mann V.M., Cooper J.M., Javoy-Agid F., Agid Y., Jenner P., Schapira A.H. Mitochondrial function and parental sex effect in Huntington's disease. Lancet 1990, 336:749.
5. Browne S.E., Beal M.F. The energetics of Huntington's disease. Neurochem Res 2004, 29:531-546.
6. Gu M., Gash M.T., Mann V.M., Javoy-Agid F., Cooper J.M., Schapira A.H. Mitochondrial defect in Huntington's disease caudate nucleus. Ann Neurol 1996, 39:385-389.
7. Panov A.V., Gutekunst C.A., Leavitt B.R., Hayden M.R., Burke J.R., Strittmatter W.J., Greenamyre J.T. Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Nat Neurosci 2002, 5:731-736.
8. Albin R.L., Greenamyre J.T. Alternative excitotoxic hypotheses. Neurology 1992, 42:733-738.
9. Djousse L., Knowlton B., Cupples L.A., Marder K., Shoulson I., Myers R.H. Weight loss in early stage of Huntington's disease. Neurology 2002, 59:1325-1330.
10. Kuhl D.E., Markham C.H., Metter E.J., Riege W.H., Phelps M.E., Mazziotta J.C. Local cerebral glucose utilization in symptomatic and presymptomatic Huntington's disease. Res Publ Assoc Res Nerv Ment Dis 1985, 63:199-209.
11. Kuwert T., Lange H.W., Langen K.J., Herzog H., Aulich A., Feinendegen L.E. Cortical and subcortical glucose consumption measured by PET in patients with Huntington's disease. Brain 1990, 113(Pt 5):1405-1423.
12. Koroshetz W.J., Jenkins B.G., Rosen B.R., Beal M.F. Energy metabolism defects in Huntington's disease and effects of coenzyme Q10. Ann Neurol 1997, 41:160-165.
13. Mastrogiacomo F., LaMarche J., Dozic S., Lindsay G., Bettendorff L., Robitaille Y., Schut L., Kish S.J. Immunoreactive levels of alpha-ketoglutarate dehydrogenase subunits in Friedreich's ataxia and spinocerebellar ataxia type 1. Neurodegeneration 1996, 5:27-33.
14. Matsuishi T., Sakai T., Naito E., Nagamitsu S., Kuroda Y., Iwashita H., Kato H. Elevated cerebrospinal fluid lactate/pyruvate ratio in Machado-Joseph disease. Acta Neurol Scand 1996, 93:72-75.
15. Ferrante R.J. Mouse models of Huntington's disease and methodological considerations for therapeutic trials. Biochim Biophys Acta 2009, 1792:506-520.
16. Ellington W.R., Suzuki T. Early evolution of the creatine kinase gene family and the capacity for creatine biosynthesis and membrane transport. Subcell Biochem 2007, 46:17-26.
17. Dawson D.M., Eppenberger H.M., Kaplan N.O. Creatine kinase: evidence for a dimeric structure. Biochem Biophys Res Commun 1965, 21:346-353.
18. Venkataraman P., Krishnamoorthy G., Selvakumar K., Arunakaran J. Oxidative stress alters creatine kinase system in serum and brain regions of polychlorinated biphenyl (Aroclor 1254)-exposed rats: protective role of melatonin. Basic Clin Pharmacol Toxicol 2009, 105:92-97.
19. Stack E.C., Matson W.R., Ferrante R.J. Evidence of oxidant damage in Huntington's disease: translational strategies using antioxidants. Ann N Y Acad Sci 2008, 1147:79-92.
20. Tachikawa M., Fukaya M., Terasaki T., Ohtsuki S., Watanabe M. Distinct cellular expressions of creatine synthetic enzyme GAMT and creatine kinases uCK-Mi and CK-B suggest a novel neuron-glial relationship for brain energy homeostasis. Eur J Neurosci 2004, 20:144-160.
21. Kowall N.W., Ferrante R.J., Martin J.B. Patterns of cell loss in Huntington's disease. Trends Neurosci 1987, 10:24-29.
22. Perluigi M., Poon H.F., Maragos W., Pierce W.M., Klein J.B., Calabrese V., Cini C., De Marco C., Butterfield D.A. Proteomic analysis of protein expression and oxidative modification in r6/2 transgenic mice: a model of Huntington disease. Mol Cell Proteomics 2005, 4:1849-1861.
23. Stack E.C., Kubilus J.K., Smith K., Cormier K., Del Signore S.J., Guelin E., Ryu H., Hersch S.M., Ferrante R.J. Chronology of behavioral symptoms and neuropathological sequela in R6/2 Huntington's disease transgenic mice. J Comp Neurol 2005, 490:354-370.
24. Vonsattel J.P., Myers R.H., Stevens T.J., Ferrante R.J., Bird E.D., Richardson E.P. Neuropathological classification of Huntington's disease. J Neuropathol Exp Neurol 1985, 44:559-577.
25. Menalled L.B., Sison J.D., Dragatsis I., Zeitlin S., Chesselet M.F. Time course of early motor and neuropathological anomalies in a knock-in mouse model of Huntington's disease with 140 CAG repeats. J Comp Neurol 2003, 465:11-26.
26. Braissant O., Bachmann C., Henry H. Expression and function of AGAT, GAMT and CT1 in the mammalian brain. Subcell Biochem 2007, 46:67-81.
27. Stockler S., Schutz P.W., Salomons G.S. Cerebral creatine deficiency syndromes: clinical aspects, treatment and pathophysiology. Subcell Biochem 2007, 46:149-166.
28. Braissant O., Beard E., Torrent C., Henry H. Dissociation of AGAT, GAMT and SLC6A8 in CNS: relevance to creatine deficiency syndromes. Neurobiol Dis 2010, 37:423-433.
29. Bessman S.P., Carpenter C.L. The creatine-creatine phosphate energy shuttle. Annu Rev Biochem 1985, 54:831-862.
30. Meyer R.A., Sweeney H.L., Kushmerick M.J. A simple analysis of the "phosphocreatine shuttle". Am J Physiol 1984, 246:C365-377.
31. Tombes R.M., Shapiro B.M. Metabolite channeling: a phosphorylcreatine shuttle to mediate high energy phosphate transport between sperm mitochondrion and tail. Cell 1985, 41:325-334.
32. Van Brussel E., Yang J.J., Seraydarian M.W. Isozymes of creatine kinase in mammalian cell cultures. J Cell Physiol 1983, 116:221-226.
33. Streijger F., Oerlemans F., Ellenbroek B.A., Jost C.R., Wieringa B., Van der Zee C.E. Structural and behavioural consequences of double deficiency for creatine kinases BCK and UbCKmit. Behav Brain Res 2005, 157:219-234.
34. in 't Zandt H.J., Renema W.K., Streijger F., Jost C., Klomp D.W., Oerlemans F., Van der Zee C.E., Wieringa B., Heerschap A. Cerebral creatine kinase deficiency influences metabolite levels and morphology in the mouse brain: a quantitative in vivo 1H and 31P magnetic resonance study. J Neurochem 2004, 90:1321-1330.
35. Hersch S.M., Rosas H.D., Ferrante R.J. Neuropathology and pathophysiology of Huntington's disease. Movement disorders: neurological principles and practice 2004, 603-629. McGraw-Hill Professional. R.L. Watts, W. Koller (Eds.).
36. Damiano M., Galvan L., Deglon N., Brouillet E. Mitochondria in Huntington's disease. Biochim Biophys Acta 2010, 1802:52-61.
37. Henley S.M., Bates G.P., Tabrizi S.J. Biomarkers for neurodegenerative diseases. Curr Opin Neurol 2005, 18:698-705.
38. Hersch S.M., Gevorkian S., Marder K., Moskowitz C., Feigin A., Cox M., Como P., Zimmerman C., Lin M., Zhang L., Ulug A.M., Beal M.F., Matson W., Bogdanov M., Ebbel E., Zaleta A., Kaneko Y., Jenkins B., Hevelone N., Zhang H., Yu H., Schoenfeld D., Ferrante R., Rosas H.D. Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG. Neurology 2006, 66:250-252.
39. Smith K.M., Matson S., Matson W.R., Cormier K., Del Signore S.J., Hagerty S.W., Stack E.C., Ryu H., Ferrante R.J. Dose ranging and efficacy study of high-dose coenzyme Q10 formulations in Huntington's disease mice. Biochim Biophys Acta 2006, 1762:616-626.
40. Bogdanov M.B., Andreassen O.A., Dedeoglu A., Ferrante R.J., Beal M.F. Increased oxidative damage to DNA in a transgenic mouse model of Huntington's disease. J Neurochem 2001, 79:1246-1249.
41. Ferrante R.J., Browne S.E., Shinobu L.A., Bowling A.C., Baik M.J., MacGarvey U., Kowall N.W., Brown R.H., Beal M.F. Evidence of increased oxidative damage in both sporadic and familial amyotrophic lateral sclerosis. J Neurochem 1997, 69:2064-2074.
42. Bogdanov M., Matson W.R., Wang L., Matson T., Saunders-Pullman R., Bressman S.S., Flint Beal M. Metabolomic profiling to develop blood biomarkers for Parkinson's disease. Brain 2008, 131:389-396.
43. Bogdanov M., Brown R.H., Matson W., Smart R., Hayden D., O'Donnell H., Flint Beal M., Cudkowicz M. Increased oxidative damage to DNA in ALS patients. Free Radic Biol Med 2000, 29:652-658.
44. Aguirre N., Beal M.F., Matson W.R., Bogdanov M.B. Increased oxidative damage to DNA in an animal model of amyotrophic lateral sclerosis. Free Radic Res 2005, 39:383-388.
45. Isobe C., Abe T., Terayama Y. Levels of reduced and oxidized coenzyme Q-10 and 8-hydroxy-2'-deoxyguanosine in the CSF of patients with Alzheimer's disease demonstrate that mitochondrial oxidative damage and/or oxidative DNA damage contributes to the neurodegenerative process. J Neurol 2010, 257:399-404.
46. Heng M.Y., Detloff P.J., Albin R.L. Rodent genetic models of Huntington disease. Neurobiol Dis 2008, 32:1-9.
47. Hersch S.M., Ferrante R.J. Translating therapies for Huntington's disease from genetic animal models to clinical trials. NeuroRx 2004, 1:298-306.
48. Wyss M., Braissant O., Pischel I., Salomons G.S., Schulze A., Stockler S., Wallimann T. Creatine and creatine kinase in health and disease-a bright future ahead?. Subcell Biochem 2007, 46:309-334.
49. O'Gorman E., Beutner G., Dolder M., Koretsky A.P., Brdiczka D., Wallimann T. The role of creatine kinase in inhibition of mitochondrial permeability transition. FEBS Lett 1997, 414:253-257.
50. Klein A.M., Ferrante R.J. The neuroprotective role of creatine. Subcell Biochem 2007, 46:205-243.
51. Brustovetsky N., Brustovetsky T., Dubinsky J.M. On the mechanisms of neuroprotection by creatine and phosphocreatine. J Neurochem 2001, 76:425-434.
52. Klivenyi P., Calingasan N.Y., Starkov A., Stavrovskaya I.G., Kristal B.S., Yang L., Wieringa B., Beal M.F. Neuroprotective mechanisms of creatine occur in the absence of mitochondrial creatine kinase. Neurobiol Dis 2004, 15:610-617.